Biomarker profiling for risk of future heart failure (HFpEF) development

Watson, Chris; Gallagher, Joe; Wilkinson, Mark D.; Russell‐Hallinan, Adam; Tea, Isaac; James, Stephanie; O'reilly, James; O’Connell, Eoin; Zhou, Shuaiwei; Ledwidge, Mark; McDonald, Ken

doi:10.1186/s12967-021-02735-3

Cited by 30 publications

(27 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whilst exogenous hormone therapy in post-menopausal women is not beneficial for primary prevention, measuring endogenous hormone levels could be useful for risk stratification especially in populations known to have more androgenic profiles like in polycystic ovarian syndrome. In addition, there is evidence to also support the use of hsTroponin I alongside BNP in predicting new-onset HFpEF with similar reported effects in men and women [29,30]. Once risk of HFpEF is established, the same study also found that galectin-3 measurements could help monitor its progression over time.…”

Section: Biomarkersmentioning

confidence: 76%

Heart Failure with Reduced Ejection Fraction—Does Sex Matter?

Swaraj

Kozor

Arnott

et al. 2021

Curr Heart Fail Rep

View full text Add to dashboard Cite

Purpose of Review There is an increasing recognition of the importance of sex in susceptibility, clinical presentation, and outcomes for heart failure. This review focusses on heart failure with reduced ejection fraction (HFrEF), unravelling differences in biology, clinical and demographic features and evidence for diagnostic and therapeutic strategies. This is intended to inform clinicians and researchers regarding state-of-the-art evidence relevant to women, as well as areas of unmet need. Recent Findings Females are well recognised to be under-represented in clinical trials, but there have been some improvements in recent years. Data from the last 5 years reaffirms that women presenting with HFrEF women are older and have more comorbidities like hypertension, diabetes and obesity compared with men and are less likely to have ischaemic heart disease. Non-ischaemic aetiologies are more likely to be the cause of HFrEF in women, and women are more often symptomatic. Whilst mortality is less than in their male counterparts, HFrEF is associated with a bigger impact on quality of life in females. The implications of this for improved prevention, treatment and outcomes are discussed. Summary This review reveals distinct sex differences in HFrEF pathophysiology, types of presentation, morbidity and mortality. In light of this, in order for future research and clinical medicine to be able to manage HFrEF adequately, there must be more representation of women in clinical trials as well as collaboration for the development of sex-specific management guidelines. Future research might also elucidate the biochemical foundation of the sex discrepancy in HFrEF.

show abstract

Section: Biomarkersmentioning

confidence: 76%

Heart Failure with Reduced Ejection Fraction—Does Sex Matter?

Swaraj

Kozor

Arnott

et al. 2021

Curr Heart Fail Rep

View full text Add to dashboard Cite

show abstract

“…To measure galectin-3 concentration in circulation, three studies (6,7,15) used Abbot Laboratories' Architect System, one study (12) used a human galectin-3 assay kit , another (2) used a Quantikine USA kit, and the rest all used enzyme-linked immunosorbent assays (ELISAs) from various manufacturers. Detailed galectin-3 measurement information, including storage temperature and storage duration (where provided), is shown in Table 4.…”

Section: Discussionmentioning

confidence: 99%

Galectin-3 and Heart Failure with Preserved Ejection Fraction: Clarifying an Emerging Relationship

Baccouche¹,

Rhodenhiser

2023

Preprint

View full text Add to dashboard Cite

Introduction: HFpEF is one of the leading causes of death whose burden is estimated to expand in the coming decades. This paper examines the relationship between circulating levels of galectin 3, an emerging risk factor for cardiovascular disease, and the clinical diagnosis of HFpEF. Methods: The authors reviewed peer-reviewed literature and 18 studies met inclusion criteria. Study characteristics, study outcome definitions, assay characteristics, main findings, and measures of association were tabulated and summarized. Results: Five studies found significant associations between galectin 3 and HFpEF diagnosis compared to healthy controls, and one did not. Five studies found significant associations between galectin 3 concentration in circulation and severity of diastolic dysfunction. Three studies found a statistically significant association between circulating galectin 3 and all-cause mortality or rehospitalization. Two studies found levels of circulating galectin 3 to be a statistically significant predictor of later HFpEF onset. Finally, two studies examined whether galectin 3 was associated with incident HFpEF, one found a significant association and the other did not. Conclusion: Given the paucity of effective therapeutics for HFpEF, galectin 3 shows promise as a possible HFpEF-linked biomarker that may, with further study, inform and predict treatment course to reduce morbidity and mortality.

show abstract

“…Interestingly, the association between SLPI and HF was driven by incident HFpEF but not HFrEF upon subgroup analysis. This differential association is notable because while many circulating proteins are associated with incident HFrEF, there are very few specific for incident HFpEF [23][24][25][26][27][28] . The SLPI-HFpEF association is also in accordance with the different contributions of inflammation to the pathophysiology of HFpEF as compared with HFrEF 29 .…”

Section: Discussionmentioning

confidence: 99%

Secretory leukocyte protease inhibitor and risk of heart failure in the Multi-Ethnic Study of Atherosclerosis

Sawicki

Nannini

Bielinski

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Circulating protease inhibitors are important regulators of inflammation that are implicated in the pathophysiology of heart failure (HF). Secretory leukocyte protease inhibitor (SLPI) is a serine protease inhibitor which protects pulmonary tissues against inflammatory damage; however, its role in HF is not well understood. We sought to evaluate associations of circulating SLPI and genetically-mediated serum SLPI with incident HF and its subtypes in a multi-ethnic cohort of adults using clinical and genetic epidemiological approaches. Among 2,297 participants in the Multi-Ethnic Study of Atherosclerosis (MESA), each doubling of serum SLPI was independently associated with incident HF (HR 1.77; 95% CI 1.02–3.02; P = 0.04), particularly incident HF with preserved ejection fraction (HFpEF; HR 2.44; 95% CI 1.23–4.84; P = 0.01) but not HF with reduced ejection fraction (HFrEF; HR 0.95; 95% CI 0.36–2.46; P = 0.91). Previously reported circulating SLPI protein quantitative trait loci (pQTLs) were not associated with serum SLPI levels or incident HF among MESA participants. In conclusion, baseline serum SLPI levels, but not genetically-determined serum SLPI, were significantly associated with incident HF and HFpEF over long-term follow-up in a multi-ethnic cohort. Serum circulating SLPI may be a correlate of inflammation that sheds insight on the pathobiology of HFpEF.

show abstract

Biomarker profiling for risk of future heart failure (HFpEF) development

Cited by 30 publications

References 45 publications

Heart Failure with Reduced Ejection Fraction—Does Sex Matter?

Heart Failure with Reduced Ejection Fraction—Does Sex Matter?

Galectin-3 and Heart Failure with Preserved Ejection Fraction: Clarifying an Emerging Relationship

Secretory leukocyte protease inhibitor and risk of heart failure in the Multi-Ethnic Study of Atherosclerosis

Contact Info

Product

Resources

About